Vertex to acquire Crinetics for $10B, expanding its rare-disease portfolio
TL;DR Summary
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals, picking up Crinetics’ approved drug Palsonify for acromegaly and additional late-stage candidates, including a therapy for congenital adrenal hyperplasia; Crinetics stock surged after hours, and the deal stands as Vertex’s largest acquisition amid a biotech M&A boom.
- Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms STAT
- Vertex to acquire Crinetics in $10B foray into endocrine disease drugs BioPharma Dive
- Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion WSJ
- Biggest stock movers Tuesday: CRNX, RIVN, DOCN, and more Seeking Alpha
- Vertex to buy Crinetics for $10 billion in rare-diseases push Reuters
Reading Insights
Total Reads
0
Unique Readers
7
Time Saved
2 min
vs 3 min read
Condensed
88%
407 → 47 words
Want the full story? Read the original article
Read on STAT